AU2019227770B2 - Methyllactam ring compound and medicinal use thereof - Google Patents

Methyllactam ring compound and medicinal use thereof Download PDF

Info

Publication number
AU2019227770B2
AU2019227770B2 AU2019227770A AU2019227770A AU2019227770B2 AU 2019227770 B2 AU2019227770 B2 AU 2019227770B2 AU 2019227770 A AU2019227770 A AU 2019227770A AU 2019227770 A AU2019227770 A AU 2019227770A AU 2019227770 B2 AU2019227770 B2 AU 2019227770B2
Authority
AU
Australia
Prior art keywords
compound
acid
formula
reaction mixture
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019227770A
Other languages
English (en)
Other versions
AU2019227770A1 (en
Inventor
Tomoya Miura
Yoshinori TAMATANI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of AU2019227770A1 publication Critical patent/AU2019227770A1/en
Application granted granted Critical
Publication of AU2019227770B2 publication Critical patent/AU2019227770B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2019227770A 2018-03-01 2019-02-28 Methyllactam ring compound and medicinal use thereof Active AU2019227770B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018-036307 2018-03-01
JP2018036307 2018-03-01
PCT/JP2019/007799 WO2019168096A1 (ja) 2018-03-01 2019-02-28 メチルラクタム環化合物及びその医薬用途

Publications (2)

Publication Number Publication Date
AU2019227770A1 AU2019227770A1 (en) 2020-07-09
AU2019227770B2 true AU2019227770B2 (en) 2023-10-05

Family

ID=67806229

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019227770A Active AU2019227770B2 (en) 2018-03-01 2019-02-28 Methyllactam ring compound and medicinal use thereof

Country Status (21)

Country Link
US (3) US11014910B2 (enExample)
EP (1) EP3760624A4 (enExample)
JP (3) JP7206132B2 (enExample)
KR (1) KR102795351B1 (enExample)
CN (1) CN111757877B (enExample)
AR (1) AR114418A1 (enExample)
AU (1) AU2019227770B2 (enExample)
BR (1) BR112020016788A2 (enExample)
CA (1) CA3087859A1 (enExample)
CL (1) CL2020002199A1 (enExample)
IL (1) IL276311B2 (enExample)
MA (1) MA52427A (enExample)
MX (1) MX2020009070A (enExample)
MY (1) MY205197A (enExample)
PE (1) PE20210123A1 (enExample)
PH (1) PH12020551340A1 (enExample)
SA (1) SA520420037B1 (enExample)
SG (1) SG11202007120UA (enExample)
TW (1) TWI805699B (enExample)
WO (1) WO2019168096A1 (enExample)
ZA (1) ZA202004600B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI805699B (zh) * 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
SG11202009179TA (en) 2018-04-04 2020-10-29 Japan Tobacco Inc Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof
CN114585387B (zh) * 2019-09-04 2024-10-29 日本烟草产业株式会社 利用联用药物的糖尿病的治疗或预防方法
KR20220156574A (ko) 2020-03-19 2022-11-25 니뽄 다바코 산교 가부시키가이샤 만성 심부전의 치료 또는 예방 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007034279A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. C3a antagonists and pharmaceutical compositions thereof
JP2007332034A (ja) * 2005-06-08 2007-12-27 Japan Tobacco Inc 複素環化合物
WO2013031922A1 (ja) * 2011-08-31 2013-03-07 日本たばこ産業株式会社 ピラゾール化合物及びその医薬用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657282A (en) * 1969-01-23 1972-04-18 Merck & Co Inc Carboxyepoxyethyl-1-phosphonic acid and derivatives
FR2665898B1 (fr) 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
JPH04247081A (ja) 1991-02-01 1992-09-03 Takeda Chem Ind Ltd ５員複素環酸アミド類
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
WO2004069824A1 (ja) 2003-02-07 2004-08-19 Daiichi Pharmaceutical Co., Ltd. ピラゾール誘導体
AU2004200420A1 (en) 2003-03-11 2004-09-30 Astellas Pharma Inc. Inhibitor of cyclooxygenase
JP2006182648A (ja) 2003-04-08 2006-07-13 Dai Ichi Seiyaku Co Ltd ７員複素環誘導体
WO2004110351A2 (en) 2003-05-14 2004-12-23 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis c virus
TW200526588A (en) 2003-11-17 2005-08-16 Smithkline Beecham Corp Chemical compounds
TW200526641A (en) 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
CA2572745A1 (en) 2004-07-07 2006-02-16 Teresa Beeson Pyrazole amide derivatives, compositions containing such compounds and methods of use
KR20070089151A (ko) 2004-11-16 2007-08-30 지더블유 파마 리미티드 카나비노이드의 새로운 용도
JP2008007405A (ja) 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
ZA200800142B (en) * 2005-06-08 2009-05-27 Japan Tobacco Inc Heterocyclic compound
EP1889842A4 (en) 2005-06-08 2009-07-29 Japan Tobacco Inc HETEROCYCLIC CONNECTION
WO2007098826A2 (en) 2006-01-18 2007-09-07 Siena Biotech S.P.A. Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
WO2007125048A1 (en) 2006-04-27 2007-11-08 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising cbx cannabinoid receptor modulators and potassium channel modulators
US20080027014A1 (en) 2006-07-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Novel SGLT inhibitors
CA2670418A1 (en) 2006-11-24 2008-05-29 Ac Immune Sa N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers's
WO2008061796A2 (en) 2006-11-24 2008-05-29 Ac Immune Sa Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
CL2008000119A1 (es) 2007-01-16 2008-05-16 Wyeth Corp Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia.
ES2466672T3 (es) 2007-04-02 2014-06-10 Theracos, Inc. Derivados de glicósido bencílico y métodos de uso
US20090181952A1 (en) 2008-01-14 2009-07-16 Wyeth Compounds useful as alpha7 nicotinic acetylcholine receptor agonists
MX2011000628A (es) 2008-07-15 2011-02-25 Novartis Ag Derivados de heteroarilo como inhibidores de dgat1.
CN110269856A (zh) 2010-03-30 2019-09-24 维颂公司 多取代芳族化合物作为凝血酶的抑制剂
TWI805699B (zh) * 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
SG11202009179TA (en) 2018-04-04 2020-10-29 Japan Tobacco Inc Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007332034A (ja) * 2005-06-08 2007-12-27 Japan Tobacco Inc 複素環化合物
WO2007034279A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. C3a antagonists and pharmaceutical compositions thereof
WO2013031922A1 (ja) * 2011-08-31 2013-03-07 日本たばこ産業株式会社 ピラゾール化合物及びその医薬用途
EP2784074A1 (en) * 2011-08-31 2014-10-01 Japan Tobacco, Inc. Pyrazole compound and use thereof for medical purposes

Also Published As

Publication number Publication date
TWI805699B (zh) 2023-06-21
IL276311A (en) 2020-09-30
PE20210123A1 (es) 2021-01-19
KR20200128033A (ko) 2020-11-11
JP7206132B2 (ja) 2023-01-17
WO2019168096A1 (ja) 2019-09-06
MX2020009070A (es) 2020-10-08
US20190352284A1 (en) 2019-11-21
CL2020002199A1 (es) 2020-12-18
IL276311B1 (en) 2023-06-01
PH12020551340A1 (en) 2021-05-31
JP2019151627A (ja) 2019-09-12
JP2023026566A (ja) 2023-02-24
MY205197A (en) 2024-10-07
SA520420037B1 (ar) 2024-07-28
JP2025026615A (ja) 2025-02-21
TW202000660A (zh) 2020-01-01
BR112020016788A2 (pt) 2021-01-12
CN111757877A (zh) 2020-10-09
US20220064148A1 (en) 2022-03-03
AR114418A1 (es) 2020-09-02
SG11202007120UA (en) 2020-08-28
US11014910B2 (en) 2021-05-25
ZA202004600B (en) 2022-03-30
KR102795351B1 (ko) 2025-04-16
RU2020131756A (ru) 2022-03-28
MA52427A (fr) 2021-01-06
US20240174646A1 (en) 2024-05-30
EP3760624A1 (en) 2021-01-06
EP3760624A4 (en) 2021-11-03
IL276311B2 (en) 2023-10-01
CN111757877B (zh) 2023-10-27
CA3087859A1 (en) 2019-09-06
AU2019227770A1 (en) 2020-07-09

Similar Documents

Publication Publication Date Title
US20240174646A1 (en) Methyllactam ring compound and pharmaceutical use thereof
US10988462B2 (en) Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof
JP2025094217A (ja) 併用医薬による糖尿病の治療又は予防方法
US20230210831A1 (en) Chronic kidney disease treatment or prevention method
RU2809634C2 (ru) Соединение с метиллактамным кольцом и его применение в фармацевтике
HK40044833A (en) Methyllactam ring compound and medicinal use thereof
RU2805312C2 (ru) Пиразольные соединения, замещенные гетероарилом, и их применение в фармацевтике
HK40067960A (en) Therapeutic or prophylactic method for diabetes using combination medicine
HK40068410A (en) Chronic kidney disease treatment or prevention method
HK40046113A (en) Heteroaryl-substituted pyrazole compound and medicinal use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)